Terns Pharmaceuticals, Inc. Stock Price, News & Analysis

Terns Pharmaceuticals reported progress on its clinical trials for three drug candidates targeting chronic myeloid leukemia, obesity, and NASH. TERN-701 is advancing to a Phase 1 trial in China, while TERN-601 is on schedule to begin a Phase 1 obesity trial in 2023. The company initiated dosing for TERN-501 in a Phase 2a trial for NASH, with results expected in the second half of 2023. As of June 30, 2022, Terns has $140 million in cash, providing a financial runway into 2025, despite a net loss of $13.9 million for the quarter.

On July 27, 2022, Terns Pharmaceuticals (Nasdaq: TERN) appointed Dr. Radhika Tripuraneni to its Board of Directors. Dr. Tripuraneni, the Chief Development Officer at Prothena Corporation, boasts over 15 years of drug development experience. She aims to leverage her expertise to guide Terns in advancing its pipeline of small-molecule candidates targeting serious diseases such as NASH, obesity, and cancer. CEO Sen Sundaram emphasized her valuable support in generating meaningful clinical data for these significant unmet needs.

Terns Pharmaceuticals presented positive results from its Phase 1 trial of TERN-501 at the EASL International Liver Congress 2022. The treatment was well-tolerated and showed significant dose-dependent effects on key biomarkers after 14 days. The company also highlighted its pipeline, including TERN-101 and TERN-201, with promising data supporting their potential in treating non-alcoholic steatohepatitis (NASH). Terns announced they will initiate a combination NASH trial with TERN-501 and TERN-101, with results expected in late 2023.

On June 8, 2022, Terns Pharmaceuticals (Nasdaq: TERN) announced that five abstracts concerning its non-alcoholic steatohepatitis (NASH) programs have been accepted for presentation at The International Liver Congress 2022, scheduled for June 22-26 in London. Key presentations include results from a first-in-human trial of TERN-501 and safety data on TERN-101 and TERN-201, showcasing their potential efficacy and favorable safety profiles. All abstracts will be published in the Journal of Hepatology.

Terns Pharmaceuticals has appointed Kerry Russell, M.D., Ph.D., as its new chief medical officer, reporting to Erin Quirk, M.D., President and Head of Research & Development. This strategic move aims to enhance Terns' expertise, particularly in progressing its clinical pipeline targeting serious diseases like non-alcoholic steatohepatitis (NASH), obesity, and chronic myeloid leukemia. With several key clinical trial data readouts expected in the coming years, Terns is focused on advancing its promising pipeline candidates.

Terns Pharmaceuticals reported advancements in its clinical pipeline, including the opening of an IND for a Phase 2a trial of TERN-501 for NASH, expected to yield top-line data in late 2023. TERN-601 is in IND-enabling studies for obesity, with a Phase 1 trial initiation anticipated in 2023. Additionally, the Phase 1 trial for TERN-701, targeting chronic myeloid leukemia, has commenced in China. The company maintains a robust cash position of $151 million, projected to sustain operations into 2025, covering three expected clinical trial readouts.

Terns Pharmaceuticals, a clinical-stage biopharmaceutical company focusing on serious diseases like NASH and obesity, will present at the 21st Annual Needham Virtual Healthcare Conference.

The presentation is scheduled for April 11, 2022, at 2:15 p.m. ET. Investors can access a live audio webcast via Terns' investor relations webpage, with a replay available for 30 days post-event.

Terns is developing a diverse pipeline of therapies, including an FXR agonist and a VAP-1 inhibitor.

FOSTER CITY, Calif., March 21, 2022 – Terns Pharmaceuticals (Nasdaq: TERN) announced top-line results from Part 1 of the Phase 1b AVIATION Trial for TERN-201, a VAP-1 inhibitor aimed at treating non-alcoholic steatohepatitis (NASH). Part 1 met the primary safety endpoint, showing TERN-201 was well-tolerated with mild to moderate adverse events, but did not demonstrate significant changes in NASH biomarkers compared to placebo. Part 2 of the trial with a higher dose is ongoing, with results expected in H2 2022. Terns maintains a cash runway into 2024 and plans further trials for other candidates.

Terns Pharmaceuticals, Inc. reported significant developments in its clinical pipeline and financial results for 2021. Expected top-line data from TERN-201's NASH trial will be released in March 2022, while TERN-501 will begin its first NASH trial in H1 2022, with results anticipated in H2 2023. The company holds $166 million in cash, providing funding into 2024. R&D expenses rose to $31.3 million, contributing to a net loss of $50.2 million for the year. Despite these losses, Terns' leadership changes and pipeline advancements position it for future growth, focusing on serious diseases like NASH and obesity.